{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:39:16Z","timestamp":1793363956137,"version":"4.5.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,21]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Checkpoint inhibitors (CPIs) have shown remarkable efficacy in Hodgkin lymphoma (HL), and are now used routinely. While allogeneic hematopoietic cell transplantation (allo-HCT) remains a curative option for HL, there are concerns prior CPIs may exacerbate post\u2013allo-HCT complications, particularly graft-versus-host disease (GVHD), and lead to worse outcomes. Given the relative paucity of data, we performed a Center for International Blood and Marrow Transplant Research\/European Society for Blood and Marrow Transplantation study to examine the impact of prior CPIs in allo-HCT. We included 2186 adult patients aged &amp;gt;18 years who received a first allo-HCT using a matched related, unrelated, or haploidentical donor from 2008 to 2023. Twenty-seven percent of patients received prior CPIs. GVHD prophylaxis was posttransplant cyclophosphamide (PTCy) in 55.8% of patients in the CPI cohort, and 35% in the non-CPI cohort. Median follow-up among survivors was longer for the non-CPI (39 months) than CPI cohort (16.5 months). In multivariate analysis, prior CPI exposure did not affect overall survival (OS) or nonrelapse mortality, but resulted in improved progression-free survival (non-CPI vs CPI hazard ratio [HR], 0.81; 0.67-0.98; P = .03) and lower relapse incidence (HR, 0.58; 0.45-0.76; P &amp;lt; 001). While grade 2 to 4 (HR, 1.26; 1.04-1.53; P = .02) and 3 to 4 (HR, 1.41; 1.04-1.92; P = .03) acute GVHD (aGVHD) were increased, differences in chronic GVHD (cGVHD) were not significant. PTCy\u2013based GVHD prophylaxis resulted in improved OS, lower grade 2 to 4 aGVHD, and cGVHD in patients with prior CPI exposure. In summary, allo-HCT should still be considered a curative option for patients with HL in the era of CPIs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024027197","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T13:58:54Z","timestamp":1751896734000},"page":"1011-1029","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"first","affiliation":[{"name":"1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-9812","authenticated-orcid":false,"given":"Farrukh T.","family":"Awan","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2552-0542","authenticated-orcid":false,"given":"Ariane","family":"Boumendil","sequence":"additional","affiliation":[{"name":"4European Society for Blood and Marrow Transplantation Lymphoma Working Party, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9301-9941","authenticated-orcid":false,"given":"Jinalben","family":"Patel","sequence":"additional","affiliation":[{"name":"5Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6239-7387","authenticated-orcid":false,"given":"Luca","family":"Castagna","sequence":"additional","affiliation":[{"name":"6Bone Marrow Transplantation Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6512-6080","authenticated-orcid":false,"given":"Emanuele","family":"Angelucci","sequence":"additional","affiliation":[{"name":"7Unit\u00e0 Operativa Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0432-9765","authenticated-orcid":false,"given":"Herve","family":"Finel","sequence":"additional","affiliation":[{"name":"4European Society for Blood and Marrow Transplantation Lymphoma Working Party, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kulagin","sequence":"additional","affiliation":[{"name":"8RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Glass","sequence":"additional","affiliation":[{"name":"9H\u00e4matologie und Zelltherapie, Helios Klinikum Berlin-Buch, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-1353","authenticated-orcid":false,"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"10Department of Pathophysiology and Transplantation, Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"11Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[{"name":"12Transplant and Cellular Immunotherapy Program, Department of Hematology, Institute Paoli Calmettes, Management Sport Cancer Lab, Aix Marseille University, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[{"name":"13Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1161-9138","authenticated-orcid":false,"given":"Khalid","family":"Halahleh","sequence":"additional","affiliation":[{"name":"14Adult Bone Marrow Transplantation Program, Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"15Departments of Lymphoma and Myeloma, and Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8401-7306","authenticated-orcid":false,"given":"Carmen","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"16Stem Cell Transplantation Unit, Hematology Department, Hospital Cl\u00ednic of Barcelona, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4827-4401","authenticated-orcid":false,"given":"Sebastian","family":"Giebel","sequence":"additional","affiliation":[{"name":"17Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3006-9725","authenticated-orcid":false,"given":"Silvia","family":"Montoto","sequence":"additional","affiliation":[{"name":"18Department of Haemato-oncology, St Bartholomew\u2019s Hospital, Barts Health NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[{"name":"19Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-4982","authenticated-orcid":false,"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[{"name":"20Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center, Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C.","family":"Lynch","sequence":"additional","affiliation":[{"name":"21Clinical Research Division, Fred Hutch Cancer Center and Medical Oncology Division, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8568-4522","authenticated-orcid":false,"given":"Marcos J.","family":"De Lima","sequence":"additional","affiliation":[{"name":"22Department of Hematology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"21Clinical Research Division, Fred Hutch Cancer Center and Medical Oncology Division, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig S.","family":"Sauter","sequence":"additional","affiliation":[{"name":"23Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4567-8037","authenticated-orcid":false,"given":"Kwang W.","family":"Ahn","sequence":"additional","affiliation":[{"name":"5Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"},{"name":"24Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"5Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"},{"name":"25Bone Marrow Transplantation and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[{"name":"26Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"27Clinical Hematology Department, Institut Catala d'Oncologia\u2013L\u2019Hospitalet, Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"19","key":"2025082111221604100_bib1","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"issue":"18","key":"2025082111221604100_bib2","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9980","key":"2025082111221604100_bib3","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"2025082111221604100_bib4","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2025082111221604100_bib5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood.V124.21.289.289","article-title":"Nivolumab in patients with relapsed or refractory Hodgkin lymphoma - preliminary safety, efficacy and biomarker results of a phase I study","volume":"124","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"14","key":"2025082111221604100_bib6","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"31","key":"2025082111221604100_bib7","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"2025082111221604100_bib8","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025082111221604100_bib9","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood.2022019386","article-title":"Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma","volume":"142","author":"Armand","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2025082111221604100_bib10","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bbmt.2015.02.022","article-title":"Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Perales","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"2025082111221604100_bib11","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbmt.2005.09.009","article-title":"Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a Spanish prospective cooperative protocol","volume":"12","author":"Alvarez","year":"2006","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"2025082111221604100_bib12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.20.01447","article-title":"Is there still a role for allogeneic transplantation in the management of lymphoma?","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025082111221604100_bib13","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2019.05.025","article-title":"Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin lymphoma","volume":"25","author":"Ahmed","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"2025082111221604100_bib14","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bjh.16664","article-title":"Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma","volume":"190","author":"Ahmed","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"2025082111221604100_bib15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/hematology.2024000575","article-title":"When to use stem cell transplantation for classical Hodgkin lymphoma","volume":"2024","author":"Perales","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"2025082111221604100_bib16","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/bmt.2016.357","article-title":"Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era","volume":"52","author":"Hegerova","year":"2017","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2025082111221604100_bib17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.15152","article-title":"Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party","volume":"181","author":"Bazarbachi","year":"2018","journal-title":"Br J Haematol"},{"issue":"10","key":"2025082111221604100_bib18","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2025082111221604100_bib19","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41375-021-01193-6","article-title":"Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma","volume":"35","author":"Merryman","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"2025082111221604100_bib20","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.bbmt.2020.06.012","article-title":"Non-myeloablative allogeneic transplantation with post-transplant cyclophosphamide after immune checkpoint inhibition for classic Hodgkin lymphoma: a retrospective cohort study","volume":"26","author":"Paul","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"2025082111221604100_bib21","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"issue":"27","key":"2025082111221604100_bib22","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025082111221604100_bib23","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"2025082111221604100_bib24","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"issue":"25","key":"2025082111221604100_bib25","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"2025082111221604100_bib26","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National marrow donor program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15","key":"2025082111221604100_bib27","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1182\/bloodadvances.2022007596","article-title":"Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant","volume":"6","author":"Jimenez Jimenez","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"2025082111221604100_bib28","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"14","key":"2025082111221604100_bib29","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"issue":"28","key":"2025082111221604100_bib30","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025082111221604100_bib31","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaoncol.2022.7975","article-title":"Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial","volume":"9","author":"Bryan","year":"2023","journal-title":"JAMA Oncol"},{"issue":"10","key":"2025082111221604100_bib32","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.clml.2024.05.017","article-title":"Phase I trial of brentuximab vedotin plus cyclosporine in relapsed\/refractory Hodgkin lymphoma","volume":"24","author":"Thiruvengadam","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"23","key":"2025082111221604100_bib33","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 Study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025082111221604100_bib34","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1159\/000481800","article-title":"Checkpoint inhibition in Hodgkin lymphoma - a review","volume":"40","author":"Br\u00f6ckelmann","year":"2017","journal-title":"Oncol Res Treat"},{"issue":"11","key":"2025082111221604100_bib35","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2025082111221604100_bib36","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/bloodadvances.2019001336","article-title":"Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma","volume":"4","author":"De Philippis","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2025082111221604100_bib37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbmt.2008.11.011","article-title":"Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"15","author":"Devetten","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"2025082111221604100_bib38","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/bloodadvances.2020003556","article-title":"Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma","volume":"5","author":"Merryman","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"2025082111221604100_bib39","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/annonc\/mdw421","article-title":"Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed\/refractory Hodgkin\u2019s lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"27","author":"Genadieva-Stavrik","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"2025082111221604100_bib40","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jamaoncol.2020.1278","article-title":"Association of reduced-intensity conditioning regimens with overall survival among patients with non-Hodgkin lymphoma undergoing allogeneic transplant","volume":"6","author":"Ghosh","year":"2020","journal-title":"JAMA Oncol"},{"issue":"4","key":"2025082111221604100_bib41","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41409-017-0018-z","article-title":"Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin\u2019s lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy","volume":"53","author":"Gauthier","year":"2018","journal-title":"Bone Marrow Transpl"},{"issue":"30","key":"2025082111221604100_bib42","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","article-title":"Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: a registry study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","volume":"35","author":"Mart\u00ednez","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025082111221604100_bib43","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s41409-019-0754-3","article-title":"Is this real life? Is this just fantasy? Decreased relapse following haploidentical transplant in Hodgkin\u2019s lymphoma with posttransplant cyclophosphamide","volume":"55","author":"Mussetti","year":"2020","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"2025082111221604100_bib44","doi-asserted-by":"crossref","first-page":"184.e1","DOI":"10.1016\/j.jtct.2022.11.028","article-title":"Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas","volume":"29","author":"Mussetti","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"25","key":"2025082111221604100_bib45","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.2022015423","article-title":"Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2025082111221604100_bib46","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL Trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol"},{"issue":"12","key":"2025082111221604100_bib47","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/bloodadvances.2022008116","article-title":"Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma","volume":"7","author":"Allen","year":"2023","journal-title":"Blood Adv"},{"issue":"21","key":"2025082111221604100_bib48","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"issue":"15","key":"2025082111221604100_bib49","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"2025082111221604100_bib50","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.2024024681","article-title":"Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma","volume":"145","author":"Lee","year":"2025","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/8\/1011\/2407105\/blood_bld-2024-027197-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/8\/1011\/2407105\/blood_bld-2024-027197-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T15:22:26Z","timestamp":1755789746000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/8\/1011\/546085\/Outcomes-of-allogeneic-HCT-in-Hodgkin-lymphoma-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024027197","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,21]]},"published":{"date-parts":[[2025,8,21]]}}}